Pharmaceutical formulations comprising an immune response...

Details Pharmaceutical formulations comprising an immune response... Pharmaceutical formulations comprising an immune response...

2011-06-28

2011-06-28

Padmanabhan, Sreeni (Department: 1627)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S397000, C546S081000

Reexamination Certificate

active

07968562

ABSTRACT:
Pharmaceutical formulations comprising an immune response modifier (IRM) chosen from imidazoquinoline amines, imidazotetrahydroquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, 1,2-bridged imidazoquinoline amines, thiazolo-quinolineamines, oxazolo-quinolinamines, thiazolo-pyridinamines, oxazolo-pyridinamines, imidazonaphthyridine amines, tetrahydroimidazonaphthyridine amines, and thiazolonaphthyridine amines; a fatty acid; and a hydrophobic, aprotic component miscible with the fatty acid are useful for the treatment of dermal associated conditions. Novel topical formulations are provided. In one embodiment, the topical formulations are advantageous for treatment of actinic keratosis, postsurgical scars, basal cell carcinoma, atopic dermatitis, and warts.

REFERENCES:
patent: 3314941 (1967-04-01), Littell et al.
patent: 4595586 (1986-06-01), Flom
patent: 4689338 (1987-08-01), Gerster
patent: 4698348 (1987-10-01), Gerster
patent: 4722941 (1988-02-01), Eckert et al.
patent: 4800076 (1989-01-01), Bhat et al.
patent: 4929624 (1990-05-01), Gerster et al.
patent: 4973468 (1990-11-01), Chiang et al.
patent: 4988815 (1991-01-01), Andre et al.
patent: 4996193 (1991-02-01), Hewitt et al.
patent: 5037986 (1991-08-01), Gerster
patent: 5175296 (1992-12-01), Gerster
patent: 5238944 (1993-08-01), Wick et al.
patent: 5266575 (1993-11-01), Gerster et al.
patent: 5268376 (1993-12-01), Gester
patent: 5346905 (1994-09-01), Gerster
patent: 5352784 (1994-10-01), Nikolaides et al.
patent: 5367076 (1994-11-01), Gerster
patent: 5389640 (1995-02-01), Gerster et al.
patent: 5395937 (1995-03-01), Nikolaides et al.
patent: 5446153 (1995-08-01), Lindstrom et al.
patent: 5482936 (1996-01-01), Lindstrom
patent: 5693811 (1997-12-01), Lindstrom
patent: 5728732 (1998-03-01), Corey et al.
patent: 5741908 (1998-04-01), Gerster et al.
patent: 5756747 (1998-05-01), Gerster
patent: 5939090 (1999-08-01), Beaurline et al.
patent: 6039969 (2000-03-01), Tomai et al.
patent: 6069149 (2000-05-01), Nanba et al.
patent: 6083505 (2000-07-01), Miller et al.
patent: 6110929 (2000-08-01), Gerster et al.
patent: 6194425 (2001-02-01), Gerster et al.
patent: 6245776 (2001-06-01), Skwierczynski et al.
patent: 6248763 (2001-06-01), Scivoletto
patent: 6331539 (2001-12-01), Crooks et al.
patent: 6376669 (2002-04-01), Rice et al.
patent: 6451810 (2002-09-01), Coleman et al.
patent: 6486168 (2002-11-01), Skwierczynski et al.
patent: 6582710 (2003-06-01), Deckers et al.
patent: 2002/0055517 (2002-05-01), Smith
patent: 2002/0058674 (2002-05-01), Hedenstrom et al.
patent: 0 394 026 (1990-10-01), None
patent: 1 104 764 (2001-06-01), None
patent: 9-208584 (1997-08-01), None
patent: 9-255926 (1999-03-01), None
patent: 11-222432 (1999-08-01), None
patent: 2000-247884 (2000-09-01), None
patent: 2001-64165 (2001-03-01), None
patent: WO 98/36747 (1998-08-01), None
patent: WO 99/29693 (1999-06-01), None
patent: WO 9929693 (1999-06-01), None
patent: WO 00/25732 (2000-05-01), None
patent: WO 00/40228 (2000-07-01), None
patent: WO 00/47719 (2000-08-01), None
patent: WO 00/76518 (2000-12-01), None
patent: WO 01/74343 (2001-10-01), None
patent: WO 02/36592 (2002-05-01), None
patent: WO 02/46188 (2002-06-01), None
patent: WO 02/46189 (2002-06-01), None
patent: WO 02/46190 (2002-06-01), None
patent: WO 02/46191 (2002-06-01), None
patent: WO 02/46192 (2002-06-01), None
patent: WO 02/46193 (2002-06-01), None
patent: WO 02/46194 (2002-06-01), None
patent: WO 02/46749 (2002-06-01), None
patent: WO 02/102377 (2002-12-01), None
Attwood, D., Florence, A. T.Surfactant Systems: Their Chemistry, Pharmacy, and Biology, New York: Chapman & Hall, 471-473, 1983.
Chollet J L et al: “Development of a Topically Active Imiquimod Formulation” Pharmaceutical Development and Technology, New York, NY, US, vol. 4, No. 1, Jan. 1999, pp. 35-43.
Miller, et al., “Imiquimod Applied Topically: a novel immune response modifier and new class of drug”,International Journal of Immunopharmacology, 21, pp. 1-14 (1999).
Wozniak, et al, “The Amination of 3-nitro-1, 5-naphthyridines by Liquid Ammonia/Potassium Permanganate1,2, A New and Convenient Amination Method.”,Journal of the Royal Netherlands Chemical Society, 102, pp. 511-513, Dec. 12, 1983.
Brennan, et al, “Automated Bioassay of Interferons in Micro-test Plates”,Biotechniques, Jun./Jul. 78, 1983.
Testerman, et al., “Cytokine Induction by the Immunomodulators Imiquimod and S-27609”,Journal of Leukocyte Biology, vol. 58, pp. 365-372, Sep. 1995.
Bachman, et al, “Synthesis of Substituted Quinolylamines. Derivatives of 4-Amino-7-Chloroquinoline”,J. Org. Chem, 15, pp. 1278-1284 (1950).
Jain, et al, “Chemical and Pharmacological Investigations of Some ω-Substituted Alkylamino-3-aminopyridines”,J. Med. Chem., 11, pp. 87-92 (1968).
Baranov, et al.,Chem. Abs. 85, 94371, (1976).
Berényi, et al, “Ring Transformation of Condensed Dihydro-as-triazines”,J. Heterocyclic Chem., 18, pp. 1537-1540 (1981).
Merck Index 10thedition, Windholtz et al Eds., Merck & Co., Rahway, NJ, 1983 abstracts 1020. 7135.

Affiliated with

Also associated with

Rating

Pharmaceutical formulations comprising an immune response... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pharmaceutical formulations comprising an immune response..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical formulations comprising an immune response... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2708542